Cargando…
Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients
A full exploration of immune responses is deserved after anti-SARS-CoV-2 vaccination and boosters, especially in the context of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although several reports indicate successful humoral responses in such patients, the literature is scarce on...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563037/ https://www.ncbi.nlm.nih.gov/pubmed/36230971 http://dx.doi.org/10.3390/cells11193010 |
_version_ | 1784808312022237184 |
---|---|
author | Clémenceau, Béatrice Le Bourgeois, Amandine Guillaume, Thierry Coste-Burel, Marianne Peterlin, Pierre Garnier, Alice Jullien, Maxime Ollier, Jocelyn Grain, Audrey Béné, Marie C. Chevallier, Patrice |
author_facet | Clémenceau, Béatrice Le Bourgeois, Amandine Guillaume, Thierry Coste-Burel, Marianne Peterlin, Pierre Garnier, Alice Jullien, Maxime Ollier, Jocelyn Grain, Audrey Béné, Marie C. Chevallier, Patrice |
author_sort | Clémenceau, Béatrice |
collection | PubMed |
description | A full exploration of immune responses is deserved after anti-SARS-CoV-2 vaccination and boosters, especially in the context of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although several reports indicate successful humoral responses in such patients, the literature is scarce on cellular specific immunity. Here, both B- (antibodies) and T-cell responses were explored after one (V3 n = 40) or two (V4 n = 12) BNT162b2 mRNA vaccine boosters in 52 allo-HSCT recipients at a median of 755 days post-transplant (<1 year n = 9). Results were compared with those of 12 controls who had received only one booster (BNT162b2 n = 6; mRNA-1273 n = 6). All controls developed protective antibody levels (>250 BAU/mL) and anti-spike T-cell responses. Similarly, 81% of the patients developed protective antibody levels, without difference between V3 and V4 (82.5% vs. 75%, p = 0.63), and 85% displayed T-cell responses. The median frequency of anti-spike T cells did not differ either between controls or the whole cohort of patients, although it was significantly lower for V3 (but not V4) patients. COVID-19 infections were solely observed in individuals having received only one booster. These results indicate that four vaccine injections help to achieve a satisfactory level of both humoral and cellular immune protection in allo-HSCT patients. |
format | Online Article Text |
id | pubmed-9563037 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95630372022-10-15 Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients Clémenceau, Béatrice Le Bourgeois, Amandine Guillaume, Thierry Coste-Burel, Marianne Peterlin, Pierre Garnier, Alice Jullien, Maxime Ollier, Jocelyn Grain, Audrey Béné, Marie C. Chevallier, Patrice Cells Article A full exploration of immune responses is deserved after anti-SARS-CoV-2 vaccination and boosters, especially in the context of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although several reports indicate successful humoral responses in such patients, the literature is scarce on cellular specific immunity. Here, both B- (antibodies) and T-cell responses were explored after one (V3 n = 40) or two (V4 n = 12) BNT162b2 mRNA vaccine boosters in 52 allo-HSCT recipients at a median of 755 days post-transplant (<1 year n = 9). Results were compared with those of 12 controls who had received only one booster (BNT162b2 n = 6; mRNA-1273 n = 6). All controls developed protective antibody levels (>250 BAU/mL) and anti-spike T-cell responses. Similarly, 81% of the patients developed protective antibody levels, without difference between V3 and V4 (82.5% vs. 75%, p = 0.63), and 85% displayed T-cell responses. The median frequency of anti-spike T cells did not differ either between controls or the whole cohort of patients, although it was significantly lower for V3 (but not V4) patients. COVID-19 infections were solely observed in individuals having received only one booster. These results indicate that four vaccine injections help to achieve a satisfactory level of both humoral and cellular immune protection in allo-HSCT patients. MDPI 2022-09-27 /pmc/articles/PMC9563037/ /pubmed/36230971 http://dx.doi.org/10.3390/cells11193010 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Clémenceau, Béatrice Le Bourgeois, Amandine Guillaume, Thierry Coste-Burel, Marianne Peterlin, Pierre Garnier, Alice Jullien, Maxime Ollier, Jocelyn Grain, Audrey Béné, Marie C. Chevallier, Patrice Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients |
title | Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients |
title_full | Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients |
title_fullStr | Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients |
title_full_unstemmed | Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients |
title_short | Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients |
title_sort | strong sars-cov-2 t-cell responses after one or two covid-19 vaccine boosters in allogeneic hematopoietic stem cell recipients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563037/ https://www.ncbi.nlm.nih.gov/pubmed/36230971 http://dx.doi.org/10.3390/cells11193010 |
work_keys_str_mv | AT clemenceaubeatrice strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients AT lebourgeoisamandine strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients AT guillaumethierry strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients AT costeburelmarianne strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients AT peterlinpierre strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients AT garnieralice strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients AT jullienmaxime strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients AT ollierjocelyn strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients AT grainaudrey strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients AT benemariec strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients AT chevallierpatrice strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients |